Mergers and Acquisitions
The Pharmaceutical and Biotechnology Industries
Herausgeber: Thomas, Mark; Rose, Janna L
Mergers and Acquisitions
The Pharmaceutical and Biotechnology Industries
Herausgeber: Thomas, Mark; Rose, Janna L
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book offers a holistic view of some of the key questions in M&As in the biotechnology and pharmaceutical industries whilst attempting to bridge the gap between theory and practice.
Andere Kunden interessierten sich auch für
- Algal Biorefinery179,99 €
- Natural Products Pharmacology and Phytochemicals for Health Care190,99 €
- Mergers and Acquisitions105,99 €
- Roger Y W TangMergers and Acquisitions in Asia58,99 €
- Moshfique UddinCross-Border Mergers and Acquisitions147,99 €
- Social Justice and Islamic Economics190,99 €
- Advances in Mergers and Acquisitions199,99 €
-
-
-
This book offers a holistic view of some of the key questions in M&As in the biotechnology and pharmaceutical industries whilst attempting to bridge the gap between theory and practice.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis Ltd (Sales)
- Seitenzahl: 212
- Erscheinungstermin: 5. April 2024
- Englisch
- Abmessung: 233mm x 156mm x 17mm
- Gewicht: 464g
- ISBN-13: 9781032157078
- ISBN-10: 1032157070
- Artikelnr.: 69923714
- Verlag: Taylor & Francis Ltd (Sales)
- Seitenzahl: 212
- Erscheinungstermin: 5. April 2024
- Englisch
- Abmessung: 233mm x 156mm x 17mm
- Gewicht: 464g
- ISBN-13: 9781032157078
- ISBN-10: 1032157070
- Artikelnr.: 69923714
Mark Thomas is Associate Dean for Programmes and Associate Professor of Strategic and Management at ICN Business School, France. He has taught Corporate Strategy and Leadership at Master and Executive Education levels including the Advanced Master's degree in Biotechnology and Pharmaceutical Management at Grenoble EM. He holds a PhD from Lancaster University Management School, UK. His research focuses on the change management process during post-merger integration. He also holds an MSc in Strategy and Management from Em-lyon, France and is a graduate of Harvard Business School. Janna Rose is a professor in People, Organizations and Society at Grenoble Ecole de Management (GEM) in France. While her teaching focuses mainly on ethics and social responsibility, as well as laboratory management and innovation, she has served as a coordinator for the Chair for Public Trust in Health and a member of the ethics board (ELSI) for EIT Health projects across Europe. Previously, she worked as a technician and manager in genomics and phytochemistry laboratories before earning degrees in Medical Anthropology (MA, Tulane University) and in Ethnobotany (PhD, Florida International University).
Chapter 1: Introduction: Taking stock of the wave of M&As in the life
sciences industry. What has the past decade taught us? Part 1: The
Pre-merger Phase Chapter 2: The Art of Letting Go: Corporate Divestitures
in the Bio-Pharmaceutical Industries Chapter 3: Preventive & Active
takeover defense strategies in the Pharmaceutical and Biotechnology
Industries Chapter 4: Merger & Acquisition trends in the Gene Therapy
sector Chapter 5: Risk management in pharmaceutical and biotechnology
mergers and acquisitions Part II: The Transaction Phase Chapter 6: Finding
the right 'fit' during the M&A process Chapter 7: Exploring all options:
unconventional acquirers in the healthcare sector Chapter 8: To make it or
buy it: Investing in M&A or R&D as contradictory or complementary
strategies in the biotech and pharma industries Chapter 9: Should
governments get involved in Big Pharma Mergers & Acquisitions? Part III:
The Post-Deal Integration Phase Chapter 10: A tale of two masters.
Assessing the post-acquisitions management strategies of private equity
firms and industrial pharmaceutical groups Chapter 11: Post-acquisition
challenges in the wake of the Covid-19 pandemic in the pharmaceutical and
biotech industry Chapter 12: Depth in biotech & pharma merger and
acquisitions. How much should you integrate? A multi-case analysis. Chapter
13: What is the 'right' speed for post-acquisition integration within the
pharmaceutical & biotechnology industries? Chapter 14: Conclusion: Future
Perspectives in Pharmaceutical and Biotechnology mergers and acquisitions
sciences industry. What has the past decade taught us? Part 1: The
Pre-merger Phase Chapter 2: The Art of Letting Go: Corporate Divestitures
in the Bio-Pharmaceutical Industries Chapter 3: Preventive & Active
takeover defense strategies in the Pharmaceutical and Biotechnology
Industries Chapter 4: Merger & Acquisition trends in the Gene Therapy
sector Chapter 5: Risk management in pharmaceutical and biotechnology
mergers and acquisitions Part II: The Transaction Phase Chapter 6: Finding
the right 'fit' during the M&A process Chapter 7: Exploring all options:
unconventional acquirers in the healthcare sector Chapter 8: To make it or
buy it: Investing in M&A or R&D as contradictory or complementary
strategies in the biotech and pharma industries Chapter 9: Should
governments get involved in Big Pharma Mergers & Acquisitions? Part III:
The Post-Deal Integration Phase Chapter 10: A tale of two masters.
Assessing the post-acquisitions management strategies of private equity
firms and industrial pharmaceutical groups Chapter 11: Post-acquisition
challenges in the wake of the Covid-19 pandemic in the pharmaceutical and
biotech industry Chapter 12: Depth in biotech & pharma merger and
acquisitions. How much should you integrate? A multi-case analysis. Chapter
13: What is the 'right' speed for post-acquisition integration within the
pharmaceutical & biotechnology industries? Chapter 14: Conclusion: Future
Perspectives in Pharmaceutical and Biotechnology mergers and acquisitions
Chapter 1: Introduction: Taking stock of the wave of M&As in the life
sciences industry. What has the past decade taught us? Part 1: The
Pre-merger Phase Chapter 2: The Art of Letting Go: Corporate Divestitures
in the Bio-Pharmaceutical Industries Chapter 3: Preventive & Active
takeover defense strategies in the Pharmaceutical and Biotechnology
Industries Chapter 4: Merger & Acquisition trends in the Gene Therapy
sector Chapter 5: Risk management in pharmaceutical and biotechnology
mergers and acquisitions Part II: The Transaction Phase Chapter 6: Finding
the right 'fit' during the M&A process Chapter 7: Exploring all options:
unconventional acquirers in the healthcare sector Chapter 8: To make it or
buy it: Investing in M&A or R&D as contradictory or complementary
strategies in the biotech and pharma industries Chapter 9: Should
governments get involved in Big Pharma Mergers & Acquisitions? Part III:
The Post-Deal Integration Phase Chapter 10: A tale of two masters.
Assessing the post-acquisitions management strategies of private equity
firms and industrial pharmaceutical groups Chapter 11: Post-acquisition
challenges in the wake of the Covid-19 pandemic in the pharmaceutical and
biotech industry Chapter 12: Depth in biotech & pharma merger and
acquisitions. How much should you integrate? A multi-case analysis. Chapter
13: What is the 'right' speed for post-acquisition integration within the
pharmaceutical & biotechnology industries? Chapter 14: Conclusion: Future
Perspectives in Pharmaceutical and Biotechnology mergers and acquisitions
sciences industry. What has the past decade taught us? Part 1: The
Pre-merger Phase Chapter 2: The Art of Letting Go: Corporate Divestitures
in the Bio-Pharmaceutical Industries Chapter 3: Preventive & Active
takeover defense strategies in the Pharmaceutical and Biotechnology
Industries Chapter 4: Merger & Acquisition trends in the Gene Therapy
sector Chapter 5: Risk management in pharmaceutical and biotechnology
mergers and acquisitions Part II: The Transaction Phase Chapter 6: Finding
the right 'fit' during the M&A process Chapter 7: Exploring all options:
unconventional acquirers in the healthcare sector Chapter 8: To make it or
buy it: Investing in M&A or R&D as contradictory or complementary
strategies in the biotech and pharma industries Chapter 9: Should
governments get involved in Big Pharma Mergers & Acquisitions? Part III:
The Post-Deal Integration Phase Chapter 10: A tale of two masters.
Assessing the post-acquisitions management strategies of private equity
firms and industrial pharmaceutical groups Chapter 11: Post-acquisition
challenges in the wake of the Covid-19 pandemic in the pharmaceutical and
biotech industry Chapter 12: Depth in biotech & pharma merger and
acquisitions. How much should you integrate? A multi-case analysis. Chapter
13: What is the 'right' speed for post-acquisition integration within the
pharmaceutical & biotechnology industries? Chapter 14: Conclusion: Future
Perspectives in Pharmaceutical and Biotechnology mergers and acquisitions